Fayez Sarofim & CO Astrazeneca PLC Transaction History

Fayez Sarofim & CO

$39.8 Billion
Q4 2024

A detailed history of Fayez Sarofim & CO transactions in Astrazeneca PLC stock. As of the latest transaction made, Fayez Sarofim & CO holds 3,643,010 shares of AZN stock, worth $279 Million. This represents 0.6% of its overall portfolio holdings.

Number of Shares

3,643,010

Previous 3,444,033 5.78%

Holding current value

$279 Million

Previous $268 Million 11.06%

% of portfolio

0.6%

Previous 0.69%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$63.2 - $79.58 $12.6 Million - $15.8 Million	198,977 Added 5.78%	3,643,010 $239 Million
Q3 2024 Nov 14, 2024	BUY	$76.67 - $87.62 $15.7 Million - $17.9 Million	204,858 Added 6.32%	3,444,033 $268 Million
Q2 2024 Aug 14, 2024	BUY	$66.81 - $80.83 $16.6 Million - $20.1 Million	248,941 Added 8.33%	3,239,175 $253 Million
Q1 2024 May 14, 2024	BUY	$61.03 - $69.57 $8.23 Million - $9.38 Million	134,784 Added 4.72%	2,990,234 $203 Million
Q4 2023 Feb 14, 2024	BUY	$61.89 - $69.28 $46.2 Million - $51.8 Million	747,234 Added 35.44%	2,855,450 $192 Million
Q3 2023 Nov 14, 2023	BUY	$64.85 - $71.7 $36.4 Million - $40.2 Million	560,934 Added 36.25%	2,108,216 $143 Million
Q2 2023 Aug 14, 2023	BUY	$69.91 - $75.81 $36 Million - $39 Million	514,755 Added 49.85%	1,547,282 $111 Million
Q1 2023 May 11, 2023	BUY	$63.15 - $71.6 $63.6 Million - $72.2 Million	1,007,832 Added 4081.12%	1,032,527 $71.7 Million
Q4 2022 Feb 13, 2023	BUY	$54.21 - $70.44 $1.34 Million - $1.74 Million	24,695 New	24,695 $1.67 Million
Q2 2022 Aug 12, 2022	BUY	$59.26 - $71.14 $198,224 - $237,963	3,345 New	3,345 $221,000

Others Institutions Holding AZN

# of Institutions

1,367

Shares Held

512M

Call Options Held

6.08M

Put Options Held

4.44M

View Full List

About ASTRAZENECA PLC

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $237B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

More about AZN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fayez Sarofim & CO, based on Form 13F filings with the SEC.

News

Stay updated on Fayez Sarofim & CO with notifications on news.

Account